In the CADM-ILD group, 80 % (four patients) of the patients who were fatal cases died from refractory ILD ≤90 days from their first visit and were positive for anti-MDA5 antibody. This evidence concerns the gene IFIH1 and clinically amyopathic dermatomyositis.